Now Watch This: Genomic Epidemiology
September 6th, 2012 1:00 pm ET - Marta Gwinn, Consultant, McKing Consulting Corp, Office of Public Health Genomics, Centers for Disease Control and Prevention
Late last year, Science magazine published a list of six Areas to Watch in 2012
Now genomic epidemiology (#4) is approaching the public health launch pad. As Science’s editors predicted, pathogen genome sequences are being used to “determine quickly where newly emerging diseases come from, whether microbes are resistant to antibiotics, and how they are moving through a population.”
This summer, two studies described the use of high-throughput whole genome sequencing (WGS) to investigate transmission of drug-resistant bacteria among hospitalized patients (Köser 2012a
These follow reports published last year of WGS applied to investigations of the massive foodborne outbreak of Shiga toxin-producing Escherichia coli O104:H4 in Europe
Falling cost and turnaround time could help transform WGS from a retrospective research technique into a tool for clinical microbiologists and public health investigators. Two timely articles (Köser 2012b
WGS will be most useful when it leads to earlier, more informed, and more cost-effective decision-making. Köser et al. suggest that:
The most compelling immediate applications for WGS are molecular epidemiology for the purposes of surveillance and outbreak investigation (e.g. for MRSA) and drug susceptibility testing for organisms that are either slow growers or difficult to culture (e.g. MTBC and HIV).
Bacterial genotyping techniques commonly used in outbreak investigations have limited power of resolution because they target only small bits of the genome. For example, although pulsed-field gel electrophoresis (PFGE) quickly identified outbreak-associated cholera isolates in Haiti, phylogenetic analysis based on WGS was required to distinguish among possible sources of the outbreak strain. Targeted genotyping is also in use for drug susceptibility testing in certain public health settings. For example, US government guidelines
Clinical translation of human WGS data is currently limited by the number of “clinically actionable” variants
Following the successful use of PFGE in a large outbreak in 1993, CDC and the Association of Public Health Laboratories (APHL)
Previous OPHG blog posts: E. Coli Sprouts in Germany and No Genome is an Island.
No hay comentarios:
Publicar un comentario